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ABSTRACT
Curcumin (from curry) (C) is highly potent against cervical cancer cells (CCC),
but poor bioavailability has limited its clinical use. Similar natural polyphenols
resveratrol (from grapes) (R), and epicatechin gallate (from green tea) (E) also display
activity against CCC. By treating CCC (HeLa) with C, E, or R, or combinations of these
compounds, we computed combination indices and observed a strong synergism among
C, E, and R at the unique molar ratio 4:1:12.5. This combination, named as TriCurin,
rapidly down regulated HPV18 E6 and NF-kB expression while concomitantly inducing
the tumor suppressor protein p53 in HeLa cells. In the mouse c-Ha-ras and HPV16 E6,
E7-expressing TC-1 CCC, both C and TriCurin elicited suppression of E6, induction of
both p53 and acetyl-p53 (activated p53), and activation of caspase-3, but the TriCurinevoked changes were several-fold greater than that produced by curcumin (4.7-fold
for E6 inhibition, and 2-fold, 6-fold, and 1.7-fold for the induction of p53, acetyl-p53,
and active caspase-3, respectively). Consequently, TriCurin was more potent in killing
TC-1 and HeLa cells. Intralesional TriCurin treatment of tumors generated in mice by
subcutaneously implanting the TC-1 CCC caused an 80–90% decrease in tumor growth.
The ability of C to eliminate HeLa cells was significantly stabilized when delivered as
TriCurin than when delivered alone. Topical application of TriCurin dispersed in a cream
base afforded efficient transfer of C across the skin. Subcutaneous TriCurin injection
yielded no adverse effect in tumor-naïve healthy mice. Thus, TriCurin is a safe and
promising therapeutic agent against HPV-associated disease.

INTRODUCTION

worldwide and poses a major threat to females especially
in the developing countries [1]. Majority of sexually
active women acquire HPV by the age of 50, which
makes cervical HPV infection the most common sexually

The human papillomavirus (HPV) is the prime
risk factor for cervical cancer that claims numerous lives
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transmitted disease in the U.S. [2]. The incidence of cervical
cancer is rather low in the developed countries because
of extensive screening programs, but the prohibitive
cost of these programs make them inappropriate for the
developing world [3]. Although the availability of two
vaccines, Cervarix® or Gardasil® [4], offer prophylactic
measures against the most common oncogenic HPV types
16/18-associated cervical lesions, effective therapeutic
measures for post-infection lesions are not currently
available. Furthermore, such vaccination programs are not
suitable for developing countries with limited resources.
During the past decade, our group has been developing
diverse strategies of potentiating the culinary component,
curcumin (C), against cancer cells in culture and also in
mouse models of melanoma, glioblastoma, and HPV+
cervical cancer [5–9]. However, due to its hydrophobicity
and rapid breakdown in vivo, curcumin per se has not been
an effective therapeutic agent [10, 11]. Using our expertise in
targeting curcumin we initially addressed the global menace
of HPV infection and cervical cancer by developing and
testing a curcumin-based cervical cream and demonstrated its
efficacy in eliminating cervical cancer cells [5]. In the current
study, we have further potentiated the antitumor efficacy of
curcumin through a simple strategy, which involves mixing
of curcumin with two other polyphenols, epicatechin gallate
(E) and resveratrol (R), at a unique synergistic molar ratio.
As an ingredient of green tea, epicatechin gallate displays
toxicity toward a wide range of cancer cells [12], and, unlike
curcumin, it is soluble in water. An important component
of grapes, resveratrol is known for its anti-oxidant, antiinflammatory, and anti-cancer properties [13]. Earlier studies
have also shown that resveratrol functions in synergism with
curcumin against cancer cells [14]. Our unique mixture of
C, E, and R (named as TriCurin) shows sharply increased
antitumor effects both in vitro as well as in vivo and can be
applied in a cream base as a safe anticancer agent that readily
permeates through the skin. Thus, we report here the design,
mechanism of action, and application of a potentiated form
of curcumin, TriCurin, as a promising therapeutic agent
against HPV-associated neoplasia.

concentrations of E while holding the concentration of R at
100 µM a ratio of C:E:R: 32 µM: 8 µM: 100 µM (or C:E:R
in the molar ratio of 4:1:12.5) was obtained that showed
selective toxicity toward cancer cells. At doses C:E:R:
4:1:12.5, C:E:R: 8:2:25, and C:E:R: 16:4:50, the fractions
of HeLa cells affected by the combination was greater than
that observed with each of the individual components C,
E, or R or the double combinations CE or CR (Figure 1C,
1D, and 1E). This ratio was named as TriCurin and the
increasing doses of C:E:R: 4:1:12.5, C:E:R: 8:2:25,
C:E:R: 16:4:50, and C:E:R: 32:8:100 were dubbed as 4
µM+, 8 µM+, 16 µM+, and 32 µM+ respectively. We next
analyzed our data in the fraction of HeLa cells affected
(killed) through Combination Index (CI) determination
using the COMPUSYN software package from ComboSyn,
Inc. (www.combosyn.com) and a strategy reported by
Chou [15]. A synergism among the components of TriCurin
at 8 µM+ and 32 µM+ was revealed when the CI at each
of these doses was found to be less than 1 (Figure 1G). In
sharp contrast, equal proportions of C, E, and R were either
antagonistic (CI >> 1) or additive (CI = 1) (Figure 1G).

TriCurin is more potent than curcumin in killing
both TC-1 and HeLa cells
In WST-1 assays, TriCurin displayed a 2.7-fold
lower IC50 than C alone for the c-Ha-ras and HPV16 E6,
E7-expressing mouse TC-1 cervical cancer cells [16] and
a 4-fold lower IC50 than C alone for HeLa cells (Table 1).

TriCurin treatment boosts p53 expression,
suppresses NF-kB, and suppresses E6 expression
in HeLa cells
We have shown earlier that 50-µM curcumin treatment
causes a dramatic induction of the cell cycle inhibitor p53 and
suppression of the pro-tumor protein NF-kB in the HeLa cells
[5]. In these experiments, we observed only a partial induction
of p53 at 32 µM C alone. However, delivering 32-µM C
along with 8-µM E and 100-µM R (i.e. TriCurin) caused a
more dramatic induction of p53 within 8 hours (Figure 2).
In this case even the combinations CE and CR caused an
induction of p53, but from three experiments, the induction
in p53 was most significant with TriCurin and CR (Figure
2B). Concomitantly, a sharp decrease in NF-kB expression
was observed in the HeLa cells following treatment with
TriCurin or CE (Figure 2C). Immunocytochemical analysis
of TriCurin-treated HeLa cells revealed a dramatic inhibition
of HPV E6 expression (Figure 2D–2F).
Although we initially used the human cervical
cancer cell line HeLa to invent the potentiated
formulation of curcumin (TriCurin), our major objective
was to test the anticancer efficacy of TriCurin in a mouse
model implanted with the mouse c-Ha-ras and HPV16
E6, E7-expressing TC-1 cells [16]. Therefore, it was
imperative for us to delineate the possible mechanism

RESULTS
Combination index measurement to obtain a
synergistic ratio of C, E, and R
The IC50 for C (17 µM) for HeLa cells was obtained
earlier using WST-1 assays [5]. In the current study, we
similarly obtained 15.5 mM and 64.6 mM as IC50 values for
E and R (for HeLa cells), respectively (Figure 1A and 1B).
Next, we conducted several pilot experiments to determine
the vulnerability of HeLa cells to those concentrations of
C, E, and R that were at or below their individual IC50
values. Our initial experiments using a mixture of C, E,
and R at their IC50 concentrations revealed toxicity even
toward normal human fibroblasts. Then, by using sub-IC50
www.impactjournals.com/oncotarget
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Table 1: Tricurin is more potent in eliminating both TC-1 and HeLa cells
Cell Lines

Curcumin
IC50 (µM)

Tricurin
IC50 (µM)

TC-1
HeLa

35
17

13
4

of TriCurin-evoked elimination of TC-1 cells. In normal
cells, the histone acetyltransferase (HAT) p300 and its
co-activator CBP bind to the cell cycle inhibitor P53 to
cause its activation through p300-mediated acetylation
[17]. In HPV+ cancer cells, the oncoprotein E6 disrupts
this P53-p300-CBP interaction by binding to both CBP
and p300 and rendering them less effective to cause p53
activation [18]. Thus, suppression of E6 expression in
the cancer cells would be expected to trigger activation
of p53 through p300-mediated acetylation of p53,
and p53-dependent expression of Bax, which triggers
apoptosis [19]. We treated cultured TC-1 cells with
vehicle, 32-mM+ TriCurin, or 32-mM curcumin and
performed a mechanistic analysis by immunostaining
for E6, active caspase-3, p53, and acetyl-p53
(Supplementary Figure S1).

TriCurin (32 mM+) treatment for 6 h caused a 19-fold
inhibition of E6 and a 9.7-fold activation of the mediator of
apoptosis caspase-3 (Figure 3C, 3F, 3I, 3J–3L). Although
32-mM curcumin alone also caused E6 suppression and
caspase-3 activation, 32-mM+ TriCurin elicited 4.7-times
greater suppression of E6 (Figure 3L) and 1.7-fold higher
activation of caspase-3 (Figure 3B, 3E, 3H–3K) than
32-mM curcumin alone after 6-h of treatment.

TriCurin is significantly more potent than
curcumin in activating P53 in TC-1 cells
Concomitant with E6 suppression, 32-mM+ TriCurin
treatment for 6 h caused an induction as well as activation
of P53 (Figure 4C, 3F, 3I, 3J–3L). Thus, compared to
vehicle-treatment, TriCurin treatment elicited a 13-fold
induction of P53 (P53 staining normalized to HOECHST)
(Figure 4K), and a 49-fold activation of P53 (Acetyl P53
staining normalized to P53 staining) (Figure 4J), thereby
resulting in a 637-fold increase in the overall level of
activated P53 (acetyl-P53 normalized to HOECHST)
(Figure 4L). Although, compared to vehicle treatment,
32-mM curcumin treatment of TC-1 cells also caused an

TriCurin is significantly more potent than
curcumin in causing suppression of E6 and
activation of caspase-3 in TC-1 cells
As expected based on the mechanisms discussed
above, compared to the vehicle-treated TC-1 cells,

Figure 1: Fraction of cells affected by C, E, R, CE, CR, and CER: measurement of combination index to identify a
synergistic formulation. (A) and (B) Concentration-dependent elimination of HeLa cells by epicatechin gallate (E) and resveratrol (R),
respectively. (C–F) Fractions of HeLa cells killed by CER at 4 μM+, 8 μM+, 16 μM+, 32 μM+, and the corresponding concentrations of
C, E, R, CE, and CR. (G) Combination index (CI) >> 1 for equimolar proportion of C:E:R: 8 μM:8 μM:8 μM (the components antagonize
one another). At CI = 1 for C:E:R: 32 μM:32 μM:32 μM, the components had an additive effect. At CI < 1 for C:E:R: 8 μM:2 μM:25 μM
and C:E:R: 32 μM:8 μM:100 μM, the components are synergistic.
www.impactjournals.com/oncotarget
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The cytotoxic activity of curcumin toward HeLa
cells is stabilized when present as a mixture in
TriCurin

induction and activation of P53 (Figure 4B, 4E, 4H, 4J–4L),
at 6 h, TriCurin treatment yielded a two-fold higher
induction of p53 (Figure 4K), and a three-fold higher
activation of p53 (Figure 4J), thereby eliciting a six-fold
higher level of activated p53 than yielded by 32-mM
curcumin alone (Figure 4L).

In order to test if the antitumor activity of C was
stabilized in the presence of E and R in TriCurin, we
incubated C alone or as TriCurin in serum-free medium
followed by treatment of HeLa cells with the medium. C,
incubated as TriCurin, but not as CE or CR or C alone
retained most of its potency to kill HeLa cells after
24 hours (Figure 6).
Additionally, we used the fluorescence from
C at 540 nm (emission) to image cells. We observed
that C from TriCurin was taken up by HeLa cells more
rapidly than from C alone (Supplementary Figure S2Supplementary Materials). Furthermore, following
incubation of C or TriCurin in the culture medium
overnight at 37°C, C from TriCurin was taken up more

Intralesional administration of TriCurin causes a
dramatic inhibition of TC-1 tumors
Anti-tumor potency of TriCurin was demonstrated
in vivo using a mouse model implanted (subcutaneously) at
the nape of the neck with the mouse cell line TC-1. Based
on the variation among volumes calculated from external
dimensions of tumors and from water displacement of
extricated tumors, intralesional administration of TriCurin
into growing tumors was observed to cause an 80–90%
decrease in tumor growth (Figure 5).

Figure 2: TriCurin causes restoration of p53 and suppression of NF-kB and E6 in HeLa cells. HeLa cells in culture were
treated with drugs for 8 h for Western blotting and for 6 h for immunocytochemistry. (A) and (B) Cells treated with the corresponding CR
and CER (32 μM+ TriCurin) show a significant increase in p53 expression. (A) and (C) Cells treated with CE and CER (32 μM+ TriCurin)
display a significant decrease in NF-kB expression in (*p < 0.05). (D–F) E6 expression is significantly suppressed following 32 μM+
TriCurin treatment (p = 0.0008) (Data expressed as mean ± S.E.M).
www.impactjournals.com/oncotarget
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efficiently than from C alone (Supplementary Figure S1).
These in vitro data support the use of TriCurin as an
efficient strategy of delivering curcumin.

Topical application of a cream formulation
of TriCurin allows permeation of curcumin
through the skin layer within 20 hours

TriCurin administration into tumor-naïve mice
causes no toxic effect

To evaluate the therapeutic applicability of TriCurin
in the form of a topical or vaginal cream, we applied a
uniform mixture of 20% TriCurin in a topical cream base
VanPen (TriCurin-VanPen) on the shaven skin of mice.
After 20 hours, the mice were terminated by injecting
ketamine-xylazine, the skin from the application site
removed, sectioned into transverse sections across the
thickness of the skin, and the sections examined at 540
nm (emission) using a confocal microscope. As shown in
Figure 8, complete permeation of C, which is fluorescent,
was observed across the entire thickness of the skin.

To test if TriCurin administration had any toxic
effect on normal tissue, tumor-naïve mice were injected
with vehicle or TriCurin (10 µl of 1.28 µM+ TriCurin)
subcutaneously at the nape of the neck, every 72 hours
for two weeks. Dissection of the injection area followed
by H&E staining and pathologic examination revealed no
sign of heightened cell death following TriCurin treatment
as compared to the vehicle-injected tissue (Figure 7).

Figure 3: TriCurin is more potent than curcumin in causing suppression of E6 and activation caspase-3 in TC-1 cells.

TC-1 cells in triplicate wells were treated with vehicle, or 32-μM curcumin, or 32-μM+ TriCurin for 2, 4, and 6 hours, fixed, and then
subjected to immunocytochemistry. (A, D, G) High E6 expression (green) and negligible active caspase-3 (red) observed after 2, 4, and
6 h of vehicle treatment. (B, E, H) Curcumin elicits a pronounced decrease in E6 and a dramatic increase in active caspase-3. (C, F, I)
TriCurin yields a more dramatic suppression of E6 and increase in caspase-3 than curcumin. Scale bar: 150 μm. (J–L) Quantification of
staining intensities from triplicate samples (two images per sample) and normalization to the corresponding HOECHST staining intensities
shows a time-dependent decrease in E6 and a progressive increase in active caspase-3 following curcumin or TriCurin treatment. Both
changes appear significantly more pronounced with TriCurin. P-values: *, **, or ***, or #: E6 levels after drug treatment compared to
vehicle-treated control (J and K) or when comparing between curcumin and TriCurin (L). Δ, Δ Δ, or Δ Δ Δ: active caspase-3 levels after drug
treatment with respect to vehicle-treated control (J and K). *Δ: p <0.04 **Δ Δ: p < 0.02 ***Δ Δ Δ: p < 0.03; #p < 0.01. Data expressed as
mean ± S.E.M.
www.impactjournals.com/oncotarget

60908

Oncotarget

We also diluted 1 ml of the 20% TriCurin-VanPen
(163 mM+ in TriCurin) 5000-fold in cell culture medium
to achieve 32 mM+ TriCurin, from which decreasing
concentrations of TriCurin were obtained by serial
dilution for the treatment of HeLa cells in culture.
Subsequent WST-1 assays faithfully reproduced the IC50
values observed with free TriCurin (Table 1), whereas
similarly diluted VanPen had no effect on the HeLa cells.
Thus, TriCurin does not lose its antitumor activity in the
TriCurin-VanPen formulation.

synergism is the proportion of the three polyphenols
in TriCurin (C:E:R: 4:1:12.5). While maintaining this
proportion, increased efficacy of TriCurin over and above
each of the three components and CE or CR was observed
at 4 mM+, 8 mM+, and 16 mM+, beyond which individual
polyphenols, CE, CR, as well as TriCurin approached a
plateau revealing the elimination of almost all HeLa cells
in in vitro cultures (Figure 1).
HPV E6 inhibits P53 through two mechanisms, one
of which entails P53 ubiquitination and degradation via
E6-P53 association [20]. A second pathway involves E6
binding to histone acetyltransferease (HAT) p300 and
its co-activator CBP, thereby inhibiting the ability of
p300 to activate the transcriptional activity of both p53
as well as NF-kB [18]. However, NF-kB affords tumor
cell protection by inducing Bcl-2 expression, whereas p53
promotes apoptosis by boosting the expression of the proapoptotic protein Bax [21]. Curcumin causes inactivation

DISCUSSION
In the current study, we have improved the efficacy
of curcumin (C) as a therapeutic agent against HPV
infection and cancer by combining it with two other
polyphenols at a unique proportion to yield a synergistic
combination, named TriCurin. The crucial factor for this

Figure 4: TriCurin is more potent than curcumin in regulating p53 in TC-1 cells. After vehicle or drug treatment of TC-1 cells

(as described in Figure 3), the cells were probed for p53 (green) and acetyl-379K-p53 (red). (A, D, G) Vehicle-treated cells show virtually no
p53 or acetyl-p53. (B, E, H) Curcumin treatment causes an increase in both p53 as well as acetyl-p53 over time. (C, F, I) TriCurin elicits
a more dramatic increase in both p53 as well as acetyl-p53 compared to curcumin. Scale bar: 150 μm. (J) Normalization of acetyl-p53 to
total p53 reveals a progressive increase in acetylation of p53 (activation) after curcumin or TriCurin treatment (compared to vehicle-treated
control), but TriCurin elicits a three-fold higher activation than curcumin after 6 h. (K) A pronounced increase in p53 expression (induction)
is observed compared to the vehicle-treated control in both curcumin as well TriCurin-treated cells, but a two-fold higher induction is
observed with TriCurin than with curcumin after 6 h of treatment. (L) The combination of activation and induction of p53 yields an overall
induction in active p53 after either curcumin or TriCurin treatment. TriCurin yields a six-fold higher induction in active p53 than curcumin
after 6 h (p < 0.005). P-values: (compared to vehicle-treated control): #p < 0.01; ▲: p < 0.005. Data expressed as mean ± S.E.M.
www.impactjournals.com/oncotarget
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of the transcription factors AP-1 and NF-kB, which have
been implicated in the transcription of HPV-associated
proteins such as E6 and E7 [22]. This curcumin-evoked
inhibition of NF-kB and the consequent suppression of E6
[21], leads to induction of p53, suppression of the NFkB-Bcl-2 protective pathway, and preferential stimulation
of the p53-Bax apoptotic pathway in cancer cells [19].
Corroboratively, we observed a dramatic activation of
caspase-3 concomitant with 32-mM+ TriCurin-evoked
suppression of E6 in the TC-1 cells (Figure 3). The
suppression of E6 and activation of caspase-3 was also
observed in the presence of 32-mM C, but the TriCurin
effect was several-fold greater than that yielded by C
alone (Figure 3). According to the studies discussed
above the TriCurin-evoked suppression of E6 should cause
decreased degradation of p53. Accordingly, we observed a
13-fold induction of p53 in the 32-mM+ TriCurin-treated
TC-1 cells with respect to the vehicle-treated cells (Figure
4). It is known that C-terminal acetylation of p53 by the
HAT p300 boosts p53’s transcriptional activity [17, 23].
Correspondingly, 32-mM+ TriCurin caused a 49-fold
increase in acetyl-p53 with respect to the vehicle-treated
control (when normalized to total p53) (Figure 4J), but
since the total p53 expression had also increased by 13fold, the overall increase in acetyl-p53 was 637-fold
with respect to the vehicle-treated control (Figure 4L).

Curcumin (32 mM) treatment also caused suppression of
E6, activation of caspase-3, and induction in p53 as well
as acetyl-p53 with respect to vehicle treatment of TC-1
cells, but the TriCurin-evoked changes were dramatically
greater in each case. Based on the reports discussed
earlier, our findings indicate that TriCurin or curcuminevoked suppression of E6 releases p53 from its inhibitory
influence thereby allowing active p53 to trigger apoptosis
in the TC-1 cells (Supplementary Figure S1).
The reason why TriCurin is strikingly more potent
than curcumin is not fully clear. Data presented in Figure
6 and Supplementary Figure S2 indicate that this higher
potency of TriCurin could be due to a combination of
stabilization as well as increased uptake of C into cells.
The current study presents a systematic analysis of
combination indices to arrive at this synergistic, highly
potent and unique anticancer formulation (TriCurin), but
further theoretical and spectroscopic analyses are required
to understand how curcumin, resveratrol, and epicatechin
gallate at this unique molar ratio interact with one another
to yield the dramatically higher anticancer and anti-HPV
properties of TriCurin.
In the animal studies, high efficacy of tumor
elimination was observed when aliquots of a 1.28
mM+ TriCurin were injected into the tumor to yield an
intra-tumor concentration of approximately 64 mM+.

Figure 5: Intralesional TriCurin treatment causes a dramatic inhibition of TC-1 tumor growth in mice. (A) Volumes of

extricated tumors from vehicle-treated and 64 μM+ TriCurin-treated mice (as measured by the displacement of water on the day of sacrifice)
(day 10). The largest, intermediate, and smallest tumors in each group are shown here. (B) Estimated volumes from external measurement
of tumors from vehicle-treated (n = 8) and TriCurin-treated (n = 9) mice. *p = 0.0003. **p = 0.00001 (Data compared between vehicletreated and TriCurin-treated on each day by two-tailed t-test with unequal variance and expressed as mean ± S.E.M).
www.impactjournals.com/oncotarget
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A dramatic inhibition of TC-1 tumor growth was observed
with TriCurin. Similar application of TriCurin to tumornaïve mice had no adverse effect on normal tissue. With
the objective of using TriCurin for topical application, we
tested our cream formulation TriCurin-VanPen, which
contained 20% TriCurin solubilized in the widely used
cream base VanPen. Application of this TriCurin-VanPen
to mouse skin demonstrated complete penetration of
curcumin within 20 hours, thus justifying the possibility of
its use in topical applications to eliminate warts. Recently,
we have also developed a cream base with FDA-approved
composition for vaginal application. Our formulation of
TriCurin in this cream base will be tested in a human trial
for HPV+ cervical dysplasia.
HPV infection leading to cervical cancer has
reached almost an epidemic level in many parts of the
developing world where appropriate vaccination programs
are not affordable for the pre-infection individuals and
screening programs are not available for the HPVinfected men and women. Although HPV infection clears
spontaneously with time in most younger women [24],

some older individuals become persistently HPV+ even in
the developed countries. In women, loop electrosurgical
excision procedure (LEEP) is commonly used to treat
high-grade dysplasia. Though highly effective, LEEP is
associated with the risk of cervical incompetence and
preterm delivery [25].
In the midst of this serious global health problem
due to HPV infection, TriCurin comes as a relatively
less expensive but highly effective therapeutic
alternative. It potently suppresses HPV E6 expression
(Figure 3), efficaciously eliminates HPV+ cells in
culture (Figure 1, Table 1), and suppresses HPV E6
and E7+ TC-1 tumors in a dramatic manner (Figure 5).
When incubated in the culture medium, curcumin
alone rapidly loses its ability to eliminate HeLa cells,
but in the TriCurin formulation, curcumin retains its
efficacy to eliminate HeLa cells (Figure 6). Based on
such properties, the use of TriCurin and its appropriate
formulations come as a relatively inexpensive but
highly promising therapeutic approach to treat HPV
infections and cervical cancer.

Figure 6: Epicatechin gallate and resveratrol stabilize curcumin’s ability to eliminate HeLa cells. Freshly prepared media

containing C (32 μM), E (8 μM), R (100 μM), CE, CR, CER, and an identical set of media incubated at 37°C for 24 h were used to
treat HeLa cells for 48 h followed by WST-1 assay. Data shown are representative of three independent experiments, each of which was
performed using triplicate samples and the results were expressed as mean ± SEM (*p ≤ 0.05 with respect to the effect of the freshlyprepared drug). The differences between the effects of freshly-prepared and incubated CER and also between incubated C and incubated
CER were insignificant (two-tailed t-test with unequal variance).
www.impactjournals.com/oncotarget
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Figure 7: TriCurin is non-toxic to tumor-naïve mouse tissue. H&E staining of tissue sections from the neck region of tumor-naïve
mice. (A) Vehicle treated mouse. (B) Mouse injected subcutaneously five times, every 72 hours, with 1.28 mM+ TriCurin (at the nape of
the neck). Enlarged views shown on the right.

Figure 8: TriCurin-VanPen applied topically allows permeation of curcumin through the skin. VanPen or 20% TriCurin-

VanPen were applied on shaven skin at the nape of the neck. After 20 h skin sections were examined using confocal microscopy. (A)
VanPen-treated skin shows no fluorescence. (B) TriCurin-VanPen treated skin shows permeation of curcumin through the skin.
www.impactjournals.com/oncotarget
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MATERIALS AND METHODS

performed using the HeLa cells. Fraction affected at each
concentration of C (in mM: 4, 8, 16, 32), at each of the
corresponding concentrations of E (in mM: 1, 2, 4, 8), R
(in mM: 12.5, 25, 50, 100), and at each of the combinations
CE, CR, and CER at the increasing combined doses was
determined. This series of data (Fractions affected) were
next analyzed using the COMPUSYN software package
from ComboSyn, Inc. (www.combosyn.com) to determine
the combination index at each of the increasing doses of
CER (4 mM+, 8 mM+, 16 mM+, 32 mM+) [15]. Using a
similar approach, combination indices for equal ratios
C:E:R: 8 mM: 8 mM: 8 mM and C:E:R: 32 mM: 32 mM: 32
mM were also determined.

Animals
Mice (C57BL6) were handled and used according to
an experimental protocol that followed NIH guidelines for
animal use and was approved by the Institutional Animal Care
Committee (IACUC) of the College of Staten Island (CUNY).

TC-1 cells
Originally created by retroviral transduction of
primary lung epithelial cells from C57BL/6 mice to
express the oncogenes HaRas, HPV16 E6 and E7, the
TC-1 cell line was a kind gift from Prof. T.-C. Wu (Johns
Hopkins Medical Institutions, Baltimore) [16].

Western blot analysis
Cells were lysed in RIPA buffer (50 mM TrisHCl, pH 8.0, 1% NP-40, 0.5% deoxycholate, 0.1%
SDS, 1 mM EDTA, 1 mM EGTA 1 mM PMSF, 50 mM
NaF, 100 mM Na4P2O7, 10 mM Na β-glycerophosphate,
1 mM Na3VO4, 1X protease inhibitor cocktail (Roche)
and quantified by Lowry protein assay. Equal amounts
of protein (20 μg) for all the cells described above were
prepared by heating samples in loading buffer composed
of 95% Laemmli sample buffer and 5% 2-mercaptoethanol
(Sigma, St. Louis, MO) in boiling water for 5 min. The
proteins were separated using 10% SDS polyacrylamide
gel electrophoresis at 100 V for 1.5 h. The electrophoretic
transfer of proteins onto a 0.45-μm nitrocellulose membrane
was performed at 200 mA constant current for 2 h on ice.
Primary antibody solutions were prepared in Tris-buffered
saline containing Tween (T-TBS; 20 mM Tris buffer, pH
7.4, 150 mM sodium chloride, 0.05 % Tween-20) and 1%
non-fat dried milk and incubated overnight. The antibody
against p53 (sc-6243) was obtained from Santa Cruz
Biotechnology (Santa Cruz, CA) and a mouse monoclonal
ß-actin antibody (SKU A2228) was procured from Sigma
(St. Louis, MO). All the primary antibodies were used at
a dilution 1:1000 except for the ß-actin antibody, which
was used at a dilution of 1:5000. The secondary antibodies,
anti-rabbit or anti-mouse were used at dilutions 1:40,000
and 1:5000 respectively. The Western blot signals were
visualized using enhanced chemiluminescence (Super
Signal West Pico, Pierce, Rockford, IL) and digitally
imaged with an Alpha Innotech imager (San Leandro, CA).
The protein bands were quantified using ImageJ and the
figures were arranged using Adobe Photoshop.

Determination of IC50 for curcumin using WST1 assay
TriCurin was serially diluted into DMEM plus
1× insulin-transferrin-selenium (ITS) supplement
(Invitrogen) and was added to the cells in 50-µl aliquot/
well. Subsequent to TriCurin treatment in triplicate wells
for 96 hours, the medium was aspirated, the cells rinsed
three times with PBS, and then 50 µl of 10% WST-1
(Clontech, Mountain View, CA) in DMEM was added to
each well. The plate was incubated at 37°C for 45 min
and absorbance monitored at 440 nm using a plate reader.
Results obtained were converted to percent control and
then analyzed using GraphPad Prism.

TriCurin
Curcumin (C) (≥ 98% curcuminoid content) (CAS
number 458-37-7) (Thermo Fisher Scientific, New Jersey,
U.S.A.; prepared by Acros Organics for Thermo Fisher;
stored at room temperature under nitrogen), (-)-epicatechin
gallate (E), and resveratrol (R) (Thermo Fisher) at the molar
proportion C:E:R: 4:1:12.5 was prepared at various doses.
A dose that contained C: E: R: (in µM) 32: 8: 100, was
named as 32 µM+ TriCurin. First a solution of 1.28 mM+
TriCurin in PBS plus 5% DMSO was prepared by dilution
from solutions of C and R in DMSO and a solution of E
in PBS. Then, 64 µM+, 32 µM+, 16 µM+, 8 µM+, 4 µM+
TriCurin solutions were prepared through serial dilution of
the 1.28 mM+ in serum-free culture medium or PBS. The
first two dilutions required addition of small increments
(2 µl) of the stock solution into an appropriate volume of
medium or PBS with vigorous and continuous vortexing.

Immunocytochemistry
HeLa and TC-1 cells (60,000 cells per well)
were plated in triplicate wells on poly-L-lysine-coated
coverslips in 24-well plates and treated with drugs after
the wells reached 80% confluence. All drug treatments
were performed in serum-free DMEM containing 1%
supplement (ITS) (insulin, transferrin, selenium; Gibco

Determination of combination index using the
COMPUSYN software package
Dose response analysis for each polyphenol (C,
E, and R) and the combinations CE, CR, and CER was
www.impactjournals.com/oncotarget
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BRL, Grand Island, NY). After treatment with 32 µM+ of
TriCurin or C for the indicated times, cells were fixed in
4% paraformaldehyde for 45 minutes at room temperature,
rinsed with phosphate buffered saline (PBS) three times
(15 min each), and blocked with 10% normal goat serum,
0.1 % Triton X-100 in PBS for 2 h. The cells were then
incubated overnight with anti-E6 antibody (sc-460, Santa
Cruz Biotechnology, Dallas, TX) (1:75) in 2% normal
goat serum, 0.1 % Triton X-100 in PBS. In mechanistic
studies, the TC-1 cells were treated with anti-E6, anti-p53
(sc-6243, Santa Cruz Biotechnology, Dallas, TX) (1:100),
anti-acetyl-379K-p53 (GTX88013, GeneTex, Inc., Irvine,
CA) (1:300), and anti-active caspase-3 (CST#9661, Cell
Signaling Technology, Danvers, MA) (1:200) antibodies
in a similar manner. The acetylated 379K position on mouse
p53 is homologous to the 382K acetylation site on the
human protein [26, 27]. Subsequent to primary antibody
treatment, the cells were washed three times with PBS and
then incubated with the respective secondary antibodies
(Alexa Fluor® 488 goat anti–mouse IgG, Alexa Fluor® 488
goat anti–rabbit IgG and Alexa Fluor® 568 goat anti–rabbit
IgG antibodies) (Life Technologies Corp., Carlsbad, CA)
in 2% normal goat serum, 0.1 % Triton X-100 in PBS
(1:1000) for 3 h and then washed three times with PBS (15
min each) followed by incubation with HOECHST33342
(HOECHST) (10 µg/ml) in PBS (10 µM) for 30 min
and three washes with PBS. The coverslips containing
stained cells were mounted on slides and cell images were
acquired using a Zeiss Axio Observer Z1 microscope and
an AxioVision 4.6.3-AP1 camera at emission wavelengths
of 460 nm (blue) 540 nm (green) and 580 (red). Images
of two different, randomly chosen fields were acquired
from each well for quantification. ImageJ (NIH, Bethesda,
MD) was used to measure the E6, p53, acetyl-379K-p53,
active caspase-3 and HOECHST fluorescence intensities.
The fluorescence intensities of all the above-mentioned
antibodies were normalized to HOECHST intensity (blue).
Since p53 displayed both induction as well as acetylationmediated activation, the HOECHST-normalized staining
intensities were expressed as acetyl-379K-p53/p53, p53/
HOECHST and acetyl-379K-p53/HOECHST.

treatment was conducted on days 1 (i.e. at approximate
length of 0.5-cm), 4, and 7. Tumor dimensions were
measured using a caliper before each treatment and in the
end, 72 hours after the third TriCurin treatment (tumor
dimension = length × width × height × 0.5). Subsequently,
the mice were sacrificed, tumors extricated, and the final
tumor volumes were measured again by displacement of
water.

Toxicity tests for TriCurin
Three 3-month-old female mice in each of two
groups were administered (subcutaneously, at the nape of
the neck) PBS, or 10 ml 1.28 mM+ TriCurin (every 72
hours) for two weeks. Subsequently, the injection area
of each mouse was dissected into tissue sections, which
were stained with hematoxylin and eosin (H&E) for
histopathologic examination by a pathologist (L.M.O).

Topical TriCurin-VanPen cream
Curcumin 1.5 g, Epicatechin Gallate 0.5 g,
Resveratrol 3.0 g and 20.0 g VanPen base cream
(Professional Compounding Centers of America, Inc.,
PCCA, Houston, TX) were mixed thoroughly as follows:
10 g of VanPen was placed in the mixing chamber of a
pharmaceutical-grade mixer (Electronic Mortar and
Pestle Ungulator 2100 by GAKO International, München,
Germany), C, E, R, powders were added to it, then 10 g
of VanPen was added on top of the mixture, and the
ingredients were mixed thoroughly with a motor-driven
rod with blades until a uniform, yellow emulsion was
obtained. This yielded approximately 25 ml of the 20%
TriCurin-VanPen cream (163 mM+ in TriCurin).

Statistical analysis
Statistical analyses were performed using Microsoft
Excel® 2007 (Microsoft Corporation, Redmond, WA) and
GraphPad Prism® 5 (GraphPad Software, Inc., La Jolla,
CA). Means and standard deviations were calculated for
each treatment and converted to percent carrier-treated.
Half maximal inhibitory concentration (IC50) values
were obtained after performing regression analyses.
Significance was assessed using two-tailed t-test with
unequal variance for comparison between two groups
and one-way ANOVA for comparison among three or
more data sets using Tukey for post-hoc analysis. In both
analyses, p < 0.05 was considered as significant.

In vivo studies to demonstrate anti-tumor
activity of TriCurin
TC-1 cells generated by engineering mouse lung
epithelial cells to ras and HPV16/18 E6 and E7 have
been used earlier to generate preclinical mouse models
of HPV+ cancer [16]. In our studies 50,000 TC-1 cells
were implanted subcutaneously at the nape of the neck
of two to three month-old C57BL6 mice. When the
tumors assumed the approximate length of 0.5 cm, each
tumor was marked into four quadrants and 2.5 µl of
the 1.28 mM+ TriCurin solution was infused into each
of the four quadrants every 72 hours (final estimated
concentration in the tumor: 64 mM+). Intralesional
1.28 mM+ TriCurin or vehicle (PBS plus 5% DMSO)
www.impactjournals.com/oncotarget
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